BioSpace News Archive

New research published in the Journal of Medicinal Food suggests eating prunes each day can improve risk factors for cardiovascular disease (CVD) including raising antioxidant capacity and reducing inflammation among healthy, postmenopausal women.

AcuSurgical, a French startup developing novel robots and procedures for the retina and ophthalmology surgery markets, announces the appointment of Michael Brownell as Chairman of the Board.

Vaccination programs aimed at controlling the impact of COVID-19 have proceeded at an unprecedented pace; the positive impact of which is clear when examining case counts in jurisdictions that have seen an efficient immunization rollout.

To drive brand awareness of, and access to, HaluGen’s Psychedelics Genetic Test Kit

Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2 diabetes.

HUTCHMED Limited announces that AstraZeneca PLC and HUTCHMED’s savolitinib has been granted conditional approval in China for the treatment of patients with non-small cell lung cancer with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.

Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in the UK at NHS Trust on June 11, 2021 by Dr. Pareeta Patel and Professor. Nick Watkin.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX® SC in the European Union.

The Honourable Marie-Claude Bibeau, Minister of Agriculture and Agri-Food announced that the Canadian Food Inspection Agency and the Singapore Food Agency have agreed to an African swine fever zoning arrangement to allow for the safe trade of swine products from disease-free zones in Canada in the event of an ASF outbreak.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.